CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
IMO-3100 at 0.16 mg/kg +2 moredrug
Likely dose
IMO-3100 at 0.16 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01622348
NCT01622348Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Idera Pharmaceuticals, Inc.·interventional·Posted Jun 19, 2012·Updated Jan 9, 2018

In Brief

A Phase 2 clinical trial evaluating IMO-3100 at 0.16 mg/kg, Saline for Injection, and 1 other intervention for Actively Extending Plaque Psoriasis and Moderate to Severe Plaque Psoriasis. Completed, enrolled 44 participants across 13 sites.

Detailed Summary

The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 19, 2012
Enrollment StartMay 1, 2012
Primary CompletionNov 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.0 years ago

Interventions

IMO-3100 at 0.16 mg/kgdrug

IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection

Saline for Injectiondrug

Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL

IMO-3100 at 0.32 mg/kgdrug

IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection